Abstract:IMPORTANCE: Approximately half of newly-diagnosed hepatocellular carcinoma (HCC) cases in the world occur in China, with hepatitis B virus (HBV) infection being the predominant risk factor. Recently, the guidelines for the management of Chinese HCC patients were updated.OBJECTIVE: The past decade has witnessed a great improvement in the management of hepatocellular carcinoma (HCC). This study reviews the recommendations in the 2019 Chinese guidelines and makes comparison with the practices from the Western world.EVIDENCE REVIEW: The updated recommendations on the surveillance, diagnosis, and treatment algorithm of HCC in the 2019 Chinese guidelines were summarized, and comparisons among the updated Chinese guidelines, the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) guidelines were made.FINDINGS: Besides imaging and pathological diagnoses, novel biomarkers like the seven-micro-RNA panel are advocated for early diagnoses and therapeutic efficacy evaluation in the updated Chinese guidelines. The China liver cancer (CNLC) staging system, proposed in the 2017 guidelines, continues to be the standard model for patient classification, with subsequent modifications and updates being made in treatment allocations. Compared to the Barcelona Clinic Liver Cancer (BCLC) system, the CNLC staging system employs resection, transplantation, and transarterial chemoembolization (TACE) for more progressed HCC. TACE in combination with other regional therapies like ablation or with systemic therapies like sorafenib are also encouraged in select patients in China. The systemic treatments for HCC have evolved considerably since lenvatinib, regorafenib, carbozantinib, ramucirumab and immune checkpoint inhibitors (ICIs)were first prescribed as first-line or second-line agents.CONCLUSIONS AND RELEVANCES: Novel biomarkers, imaging and operative techniques are recommended in the updated Chinese guideline. More aggressive treatment modalities are suggested for more progressed HBV-related HCC in China.

[Chinese guidelines on the management of hepatic encephalopathy in cirrhosis (2024)]

Chinese guidelines on management of hepatic encephalopathy in cirrhosis

Chinese Guidelines On The Management Of Liver Cirrhosis (Abbreviated Version)

Chinese guidelines on the management of ascites in cirrhosis : Chinese Society of Hepatology, Chinese Medical Association

Clinical Neurorestorative Therapeutic Guideline for Brainstem Hemorrhage (2020 China Version)

Guideline of Clinical Neurorestorative Treatment for Brain Trauma (2022 China Version)

Chinese guidelines on the management of ascites and its related complications in cirrhosis

Chinese consensus on the management of liver cirrhosis

[Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)]

Clinical Diagnosis Guidelines And Neurorestorative Treatment For Chronic Disorders Of Consciousness (2021 China Version)

Guidelines of prevention and treatment for alcoholic liver disease (2018, China).

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

Chinese Clinical Practice Guidelines for the Prevention and Treatment of Mother-to-Child Transmission of Hepatitis B Virus (version 2024)

Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)

Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma

Chinese Consensus on Clinical Diagnosis and Therapy of Liver Cirrhosis

Critical Appraisal of Chinese 2017 Guideline on the Management of Hepatocellular Carcinoma.

A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights

Diagnosis and Management of Hepatic Encephalopathy

Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)

Guidelines for the Diagnosis and Management of Alcoholic Liver Disease: Update 2010